Taysha Gene Therapies, Inc. Assets Held-for-sale, Not Part of Disposal Group, Current
Taysha Gene Therapies, Inc. (TSHA) had Assets Held-for-sale, Not Part of Disposal Group, Current of $2.00 million as of 2024-06-30, per its 10-Q filed 2024-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent · last filed 2025-02-26
- 2024-06-30: Assets Held-for-sale, Not Part of Disposal Group, Current $2.00M.
- 2024-03-31: Assets Held-for-sale, Not Part of Disposal Group, Current $2.00M.
- 2023-12-31: Assets Held-for-sale, Not Part of Disposal Group, Current $2.00M.
- 2023-09-30: Assets Held-for-sale, Not Part of Disposal Group, Current $2.00M.
| Period end | Assets Held-for-sale, Not Part of Disposal Group, Current |
|---|---|
| 2024-06-30 | $2.00M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $2.00M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $2.00M 10-K · filed 2025-02-26 |
| 2023-09-30 | $2.00M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |